In a Phase 3 head-to-head trial, the company compared CagriSemas performance with that of Lillys tirzepatide, which is known to achieve greater weight loss than semaglutide
The researchers found that for the treatment regimen estimand, the mean change from baseline in hemoglobin A1c concentration was 1.69, 1.86, and 1.94 percent with 4, 9, and 12 mg of retatrutide, respectively, versus 0.81 percent with placebo, resulting in estimated treatment differences of 0.88, 1.04, and 1.12 percent, respectively, versus placebo
USA 84 , 34343438 (1987)
Ginzler, E
Participants were randomly assigned to different treatment groups, allowing researchers to evaluate a range of starting doses, dose-escalation approaches, and maintenance doses